Tessari Eben

KNSA COO Tessari sells 12,048 shares at $41.56; holding drops 42.0% to 16.7K; stock up 15.4% in 90 days.

Tessari Eben, Chief Operating Officer, sold 12,048 shares at $41.56, reducing his holdings by 42.0% from 28.7K to 16.7K shares. The stock has traded favorably in recent months, up 15.4% over the past 90 days and currently near its 52-week high at $41.47 (down only 2.9% from the peak of $42.71). At the same ticker over 5 prior trades, his prior sells have consistently generated positive 90-day returns (ranging from +12.4% to +14.1% on the two measured sales), indicating his recent sales at KNSA have not preceded declines. His cross-ticker track record shows 16 prior sells with a 0.00% well-timed rate, meaning he did not sell ahead of price drops. The company's fundamentals show strong recent growth—annual revenue is up 56.6% with latest-quarter revenue of $180.9M—though it remains unprofitable on a full-year basis. This sale occurs in a context of appreciating stock price and healthy corporate momentum, without evidence of poor timing on the insider's part.

COO Tessari sells 12,470 shares (35.4% of holdings) at avg $41.24; stock now at $42.16

Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals, executed 2 separate sales totaling 12,470 shares for $514,224.10 on 2025-11-17 at an blended average price of $41.24—slightly below the current price of $42.16. The sale reduces his post-transaction holdings from 35,184 to 22,714 shares, a reduction of 35.4% of his pre-transaction position. Evaluating timing context: his cross-ticker track record shows an average 90-day return of +18.8% after prior sells with a 0.00% well-timed rate, indicating those sales have historically been poorly timed (stock rose after). His same-ticker history at KNSA across 5 prior sells shows mixed near-term outcomes (30-day range from -2.5% to +8.4%), though 90-day measurement outcomes are not yet available. The company is on strong growth trajectory (revenue +56.6% year-over-year) with recent profitability ($18.4M net income on $180.9M quarterly revenue), providing fundamental backdrop for recent stock appreciation (+8.1% in 30 days, +25.6% in 90 days, now at 52-week high of $42.16). This represents a substantial reduction in CEO equity ownership during an appreciated price environment.

COO Tessari Eben sells 42,000 KNSA shares for $1.6M, reducing stake 54.9%; stock near 52-week high

Tessari Eben, Chief Operating Officer, sold 42,000 shares (42.0K shares) of KNSA at $38.33 on 2025-09-29, reducing his holdings from 76,552 shares to 34,552 shares—a decline of -54.9% vs pre-transaction holdings. The transaction occurred near the stock's 52-week high of $38.83, with the stock currently trading at $38.64 (-0.5% from 52-week high) and having appreciated +15.4% over the prior 30 days and +38.6% over 90 days. This represents the fifth consecutive sell by this insider at KNSA within a 27-day span (2025-09-03 through 2025-09-29), totaling approximately 42,000 shares in this latest transaction alone. While the company shows strong recent fundamentals with +56.6% annual revenue growth and positive quarterly net income of $17,832,000 ($17.8M), context is limited by the fact that full-year net income was negative, leaving the company's trajectory uncertain. The pattern of consecutive sales at elevated prices warrants attention, though all same-ticker outcomes remain unmeasurable as of this filing.

COO Tessari sells 16.4K shares in 2 transactions for $597,975.80, reducing stake by 32.2%

Eben Tessari, Chief Operating Officer at Kiniksa Pharmaceuticals, executed 2 separate sales totaling 16,400 shares for $597,975.80 on 2025-09-15, reducing his holdings from 50,952 shares to 34,552 shares. The sales occurred at a blended average price of $36.46, near the 52-week high of $37.10. This follows a pattern of recent selling activity at KNSA: Tessari sold shares on 2025-09-05, 2025-09-04, and 2025-09-03, indicating concentrated liquidation over a short window. His cross-ticker track record shows a 0.00% well-timed rate across 11 prior sells, suggesting his historical sale timing has not preceded subsequent stock declines. While the company posted revenue of $156,797,000.00 and net income of $17,832,000.00 in the latest quarter with annual revenue growth of +56.6%, it was unprofitable over the full fiscal year, indicating uneven operational performance beneath the quarterly surface.

COO Tessari Eben sold 98.7K shares (68.9% of holdings) at $35.52–$35.66 on Sept 4–5; stock near 52-week high.

Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals, executed 2 separate sales totaling 98,660 shares for $3,506,277.66 at blended average price $35.54, reducing his holdings from 143,112 shares to 44,452 shares. The sales occurred as the stock traded near its 52-week high of $36.57 (current price) and after a strong 13.8% gain in the prior 30 days and 22.8% gain over 90 days. His prior trades at KNSA show mixed recent activity (4 sells on Aug 5, Aug 18, and Sept 3, all within the past month) with measured 30-day returns of +7.0% and +4.8% on the Aug 5 sales, though 90-day outcomes remain incomplete. Cross-ticker, his track record of 9 prior sells averaged +1.8% over 30 days and +18.8% over 90 days with a 0.00% well-timed rate, indicating his prior sells did not typically precede declines. The company posted $156,797,000 in latest-quarter revenue with +56.6% annual revenue growth, though it remains unprofitable on a full-year basis.

Kiniksa COO Tessari Eben sold 15,091 shares at $35.50 on 2025-09-03, reducing stake 25.3% while stock trades at 52-week high.

Eben reduced his Kiniksa holding by 25.3%, selling 15,091 shares for $535,730.50 at $35.50, a price that matches the 52-week high of $35.48 currently quoted. This sale follows four other sales in the past month (August 5, 18), suggesting a pattern of regular disposition. The company's fundamentals show robust growth—annual revenue growth of +56.6% and latest-quarter revenue of $156,797,000.00 with net income of $17,832,000.00—but this masks full-year unprofitability. The stock has appreciated +7.7% over 30 days and +20.2% over 90 days; his cross-ticker track record shows an average 30-day return of -0.2% following prior sells, and among his five prior KNSA trades, only one measurable outcome (the July 14 sell) has been recorded at 90 days, with a +17.2% return. The timing of this sale precisely at the 52-week high warrants observation, though no definitive pattern of well-timed or poorly-timed selling can yet be established at this ticker given the limited measurable outcomes.

COO Tessari Eben sells 16,200 shares for $547,141.00 at KNSA; stock near 52-week highs (+28.0% in 90 days)

Tessari Eben, Chief Operating Officer, executed two separate sales totaling 16,200 shares for $547,141.00 on 2025-08-18, reducing his holdings by 28.7% from 56,415 to 40,215 shares. The transactions occurred at prices ($33.77 and $34.44) near the company's 52-week high of $33.72, with the stock having appreciated 28.0% over the prior 90 days and 16.8% over the prior 30 days. Kiniksa posted strong recent fundamentals—revenue of $156,797,000.00 in the latest quarter, net income of $17,832,000.00, and annual revenue growth of +56.6%—though the company remains unprofitable on a full-year basis. The sale's timing at near-peak valuations combined with outsized recent gains warrants monitoring to determine whether this reflects a structural shift in insider positioning or a response to the stock's elevated technical levels.

COO Tessari Eben sold 138.6K shares (73.5% of holdings) at $33.20 avg; stock at 52-week high.

COO Tessari Eben executed 2 separate sales totaling 138,614 shares for $4,602,369.80, reducing his holdings by 73.5% from 188.5K to 49.9K shares. The sales occurred at prices ($33.20 and $33.90 blended to $33.20) that match the current price of $33.11—essentially at the 52-week high. His prior sales at KNSA have shown mixed post-transaction outcomes: three of four measurable sales resulted in 30-day declines of 5.0% to 7.9%, though his cross-ticker track record averages a -6.0% 30-day return. The company reported strong fundamentals in the latest quarter ($156.8M revenue, $17.8M net income, +56.6% annual revenue growth), though it remains unprofitable on a full-year basis. A substantial reduction of holdings at peak valuation by a senior executive bears monitoring for what it may signal about near-term management expectations.

COO Tessari Eben sold 18,900 KNSA shares at $28.72; holds 49,163 post-sale after -27.8% reduction from 68,063

Tessari Eben, Chief Operating Officer, sold 18,900 shares on 2025-07-14 for $542,808.00, reducing his holdings by 27.8% from 68,063 to 49,163 shares. This follows a pattern of three consecutive sales at KNSA in early June 2025, each followed by modest declines (30-day returns of -7.9%, -5.0%, and -5.2%), though none of his prior trades at this ticker show measurable 90-day outcomes yet. The company posted revenue of $137,785,000.00 with net income of $8,539,000.00 in the latest quarter and strong annual growth of +56.6%, though it remains unprofitable on a full-year basis. At $28.42 current price, the stock is down 6.3% from its 52-week high of $30.33 but has appreciated 40.6% over the past 90 days, leaving limited directional context for the timing of this particular sale.

COO Tessari Eben sells 70.9K shares for $2.2M across 3 sales (Jun 9–11); trims holdings 49.5% near 52-week peak

Tessari Eben, Chief Operating Officer of Kiniksa Pharmaceuticals, executed 3 separate sales totaling 70,867 shares for $2,160,035.40 at a blended average price of $30.48 on June 9–11, 2025. This represents a reduction of 49.5% of his pre-transaction holdings from 143,230 shares to 72,363 shares. The sales occurred within 0.4% of the 52-week high of $30.33, and the stock has gained 12.6% over the prior 30 days and 36.4% over 90 days, placing the company near its recent peak valuation. While Kiniksa posted strong recent fundamentals with revenue of $137,785,000.00 and annual growth of 56.6%, the company was unprofitable over its most recent full fiscal year, which may bear on insider capital allocation choices at elevated valuations.